Harnessing Gut Microbiota to Enhance Immunotherapy in NSCLC: From Mechanisms to Translational Applications
Liming Zhu, Jiayao Xu, Dong Niu, Xiangyu Zhang, Chunhui Jin · 2026
Read Harnessing Gut Microbiota to Enhance Immunotherapy in NSCLC: From Mechanisms to Translational Applications by Liming Zhu, Jiayao Xu, Dong Niu, Xiangyu Zhang, Chunhui Jin (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13290434.txt.
Description
Liming Zhu and colleagues review how gut microbes may raise immunotherapy power in lung cancer, in a 2026 article. Non-small cell lung cancer is the commonest lung cancer type, and checkpoint drugs help only a share of patients. Gut bacteria talk to the immune system through metabolites and direct signaling. The review gathers clinical findings on response differences tied to gut makeup and maps the gut-lung axis that may carry those effects.
People vary hugely in gut ecosystems, which makes results hard to copy. No standard protocol yet governs microbe-based add-ons such as transplants or probiotics. Safety questions also remain open for frail cancer patients. The authors build a framework covering biomarkers, intervention design, and personal matching. They argue that careful trials could turn gut tuning into a precision tool, and counsel against casual antibiotic use during immunotherapy, since it may blunt benefit.
Catalog record
| CREATOR | Liming Zhu, Jiayao Xu, Dong Niu, Xiangyu Zhang, Chunhui Jin |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 63 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |